SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA

Image of SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with
diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA

THERAPEUTIC CLASS

SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA

Sarafidis P - Personal Name;

Chronic kidney disease (CKD) in patients with diabetes mellitus (DM) is a major problem of public health. currently, many of these patients experience progression of cardiovascular and renal disease, even when receiving optimal treatment. In previous years, several new drug classes for the treatment of type 2 DM
have emerged, including inhibitors of renal sodium–glucose cotransporter-2 (SGLT-2) and glucagon-like peptide-1 (GLP-1) receptor agonists

Availability

Titan Center Location name is not set

REQJ408-01

Available

Detail Information

Series Title: -
Call Number: -
Publisher: : .,
Collation: -
Language: English
ISBN/ISSN: -
Classification: NONE
Content Type: -
Media Type: -
Carrier Type: -
Edition: -
Subject(s): Endocrine & Metabolic system
Specific Detail Info: Nephrol Dial Transplant (2019) 34: 208–230
Statement of Responsibility: -

Other version/related

No other version available

File Attachment

No Data

Comments

You must be logged in to post a comment